Mallia Aesthetics and Neomed Enter Exclusive Middle East Partnership with First 8T3 Essentials Approval Granted

• Partnership combines Mallia’s science-based products for hair regeneration with Neomed’s strong expertise in aesthetics and deep regional market network
• Neomed has already secured regulatory approval for 8T3 Essentials Hair Serum in Saudi Arabia
• Neomed to lead further regulatory approvals, distribution and market launches across several Middle Eastern markets
• 8T3 Essentials Hair Serum and 8T3 Essentials Lash & Brow Serum to be marketed directly to consumers and through dermatologists and pharmacists

Erlangen, Germany, November 05, 2026 – Mallia Aesthetics GmbH, a company focusing on the development and commercialization of cosmetic products to stimulate hair growth, and Neomed Group, a regional provider of medical, healthcare and aesthetics services in the Middle East, today announced an exclusive market access and distribution partnership to bring Mallia’s 8T3 Essentials Hair Serum and 8T3 Essentials Lash & Brow Serum to several markets across the region.

Under the agreement, Neomed will take responsibility for the regulatory approval process for both 8T3 Essentials products and, subject to approval, will lead their market launches. Neomed has already secured regulatory approval for 8T3 Essentials Hair Serum in Saudi Arabia and is preparing to launch the product there. Further approvals and launches are expected in early 2027, including in the United Arab Emirates. Neomed will leverage its established regional network and market expertise to distribute the products via a combination of direct-to-consumer channels and through dermatologists and pharmacists in the respective markets.

For Mallia, the partnership represents its first commercial collaboration outside of Europe and is an important step in the international development of its 8T3 Essentials portfolio. For Neomed, the collaboration adds to its offering a hormone-free hair growth product portfolio that is backed by decades of scientific research and successful consumer studies.

“Entering the Middle East with 8T3 Essentials is a major milestone for Mallia, and we could not imagine a stronger partner for this next phase. We have seen strong interest in our 8T3 Essentials products since their launch in Europe, and we are now taking the next step in making them available in additional markets, starting with Saudi Arabia,” said Dr. Manfred Gröppel, Co-founder and Managing Director of Mallia Innovations. “The combination of our science-based products and Neomed’s deep understanding of the regional aesthetics market, outstanding network and commercial expertise creates an excellent opportunity to bring 8T3 Essentials to a much broader audience. We look forward to together building a strong presence for the portfolio in the region.”

Elie Helou, Managing Director of Neomed, said: “We are excited to bring 8T3 Essentials to the Middle East and to partner with Mallia on this important market opportunity. We are particularly pleased to have already secured regulatory approval for 8T3 Essentials Hair Serum in Saudi Arabia. The combination of a compelling scientific foundation, an innovative approach to hair growth and convincing consumer study results makes these products particularly exciting for the region. We see strong potential for the products and are confident that our established relationships with healthcare professionals and consumers will provide an excellent platform for their launch. We look forward to introducing 8T3 Essentials to the market and building the brand together with Mallia.”

8T3 Essentials Hair Serum and 8T3 Essentials Lash & Brow Serum contain MAL-838, a proprietary cosmetic ingredient based on the naturally occurring immunomodulatory protein sCD83. The product is the result of more than 25 years of research on sCD83 led by Mallia Co-founder Prof. Dr. Alexander Steinkasserer. Positive results from a six-month consumer study with 8T3 Essentials Hair Serum showed measurable new hair growth in 70% of participants and an average increase in hair density of 30%. 8T3 Essentials Lash & Brow Serum has also shown positive results in a 12-week consumer study, with 81% of participants reporting visibly longer lashes and objective measurements showing individual increases in lash length of up to 39%.

The 8T3 Essentials Hair Serum and 8T3 Essentials Lash & Brow Serum are currently available in the European Union. With Saudi Arabia, 8T3 Essentials Hair Serum will enter its first market in the Middle East. The products will continue to be manufactured in Europe by Mallia and its manufacturing partners, with Neomed responsible for distribution and market launches in the respective Middle Eastern markets.

Mallia and Neomed will provide updates on additional markets and launch timing as further regulatory approvals are obtained.

About sCD83

Soluble CD83 (sCD83) is an immunomodulatory protein currently being developed for the topical treatment of hair loss (MAL‑856) and stimulation of hair growth (MAL‑838). The soluble CD83 protein was first identified in 2001 by Prof. Steinkasserer, a co-founder of Mallia. It possesses anti-inflammatory properties by inducing resolution of inflammation, which promotes wound healing and induces new hair growth¹. In addition, sCD83 has been shown to activate regulatory T cells (Tregs)², which can directly interact with and activate hair follicles.³ Furthermore, sCD83 inhibits cell death of hair follicle cells and directly activates follicular stem cells, as well as keratin production, thereby stimulating new hair growth. This multimodal mechanism distinguishes sCD83 from other topically applied hair growth products.

When topically applied, sCD83 directly enters the hair follicles but does not penetrate through the skin and thus does not enter the bloodstream. The effect is localized, which is a significant advantage over systemic treatment options, which can cause severe side effects.

About hair loss

Hormone-related hair loss in men and women (androgenetic alopecia, or AGA) is the most common form of hair loss. Worldwide, more than 70% of men and 50% of postmenopausal women are affected by androgenetic alopecia. An additional 147 million people suffer from immune-mediated, circular hair loss (alopecia areata, or AA^4,5).

Androgenetic alopecia usually progresses gradually and is caused by genetic and hormonal factors. In men, it often leads to a receding hairline and baldness on the top of the head, while in women it leads to thinning hair along the part. Alopecia areata causes circular patches of hair loss on the scalp, face, or other parts of the body. It occurs when the immune system erroneously attacks hair follicles, leading to immune-mediated hair loss.

About Mallia

Mallia Innovations GmbH, based in Erlangen, Germany, is the holding company strategically driving the proprietary development and commercialization of biopharmaceutical therapies and cosmetic applications based on the immunomodulatory sCD83 protein. These are aimed at hair growth, hair loss, and other dermatological indications, including wound healing.

Mallia Therapeutics GmbH focuses on the clinical development of novel therapies for patients suffering from androgenetic alopecia or alopecia areata. The active ingredient, MAL-856 is based on the scientifically proven immunomodulatory mode of action of sCD83, which has been investigated for over 25 years by Mallia Co‑founder Prof. Dr. Alexander Steinkasserer.⁶

Mallia Aesthetics GmbH focuses on cosmetic applications designed to stimulate hair growth, which are also based on the scientifically validated sCD83 protein. The company develops innovative cosmetic products based on MAL-838, which are marketed to professionals and consumers.

To purchase products from the 8T3 Essentials line, please visit our online shop: https://8t3.com/en/

For more information, visit www.mallia.com and follow us on LinkedIn, Instagram, and Facebook.

About Neomed Group

Over 20 years of experience in the Medical, Healthcare, and Aesthetics industries across the Middle East. With a forged background through multinational companies, entrepreneurships, and startups, we offer a wide range of solutions and services to be your trusted partner on your journey to better health and well-being. For more information, visit https://neomedgroup.com/

¹ Royzman, D., Peckert-Maier, K., Stich, L., König, C., Wild, A. B., Tauchi, M., … & Steinkasserer, A. (2022). Soluble CD83 improves and accelerates wound healing by the induction of pro-resolving macrophages. Frontiers in Immunology, 13, 1012647. DOI: 10.3389/fimmu.2022.1012647

² Bock, F., Rössner, S., Onderka, J., Lechmann, M., Pallotta, M. T., Fallarino, F., … & Zinser, E. (2013). Topical application of soluble CD83 induces IDO-mediated immune modulation, increases Foxp3+ T cells, and prolongs allogeneic corneal graft survival. The Journal of Immunology, 191(4), 1965-1975. DOI: 10.4049/jimmunol.1201531

³ Ali, N., Zirak, B., Rodriguez, R. S., Pauli, M. L., Truong, H. A., Lai, K., … & Rosenblum, M. D. (2017). Regulatory T cells in skin facilitate epithelial stem cell differentiation. Cell, 169(6), 1119-1129. DOI: 10.1016/j.cell.2017.05.002

⁴ Feinstein, R. P. (2022). Androgenetic alopecia.: https://emedicine.medscape.com/article/1070167-overview

⁵ Mostaghimi, A., Gandhi, K., Done, N., Ray, M., Gao, W., Carley, C., … & Sikirica, V. (2022). All-cause health care resource utilization and costs among adults with alopecia areata: A retrospective claims database study in the United States. Journal of Managed Care & Specialty Pharmacy, 28(4), 426-434: DOI: 10.18553/jmcp.2022.28.4.426

⁶ Lechmann, M., Krooshoop, D. J., Dudziak, D., Kremmer, E., Kuhnt, C., Figdor, C. G., … & Steinkasserer, A. (2001). The extracellular domain of CD83 inhibits dendritic cell–mediated T cell stimulation and binds to a ligand on dendritic cells. The Journal of experimental medicine, 194(12), 1813-1821. DOI: 10.1084/jem.194.12.1813

MRM Health and Biocodex establish strategic partnership to strengthen future commercial supply capabilities for CORAL®-based medicines

Collaboration combines MRM Health’s cutting-edge microbiome science and proprietary CORAL® platform with Biocodex’s industrialization and manufacturing capabilities

Planned €15 million investment by Biocodex in specialized anaerobic manufacturing infrastructure will establish an additional pathway for MH002 and other MRM Health programs, from clinical development toward potential commercial supply

The specialized manufacturing capacity strengthens MRM Health’s readiness for pharmaceutical partnerships while preserving manufacturing flexibility and ownership of its platform and product-related innovations    

Ghent, Belgium – November 5, 2026 – MRM Health, a clinical-stage biotech developing microbiome-based therapies for immune-mediated diseases, and Biocodex, an independent French pharmaceutical company with more than 70 years of experience in the microbiome field, today announced the launch of a strategic partnership to establish specialized manufacturing capabilities for live biotherapeutic products. The collaboration combines MRM Health’s cutting-edge microbiome science and proprietary CORAL® platform with Biocodex’s pharmaceutical development, industrialization and manufacturing capabilities.

The partnership is designed to support both MRM Health’s lead asset MH002 and other CORAL®-based programs across the product lifecycle, from process development and clinical manufacturing toward potential future commercial supply. By establishing access to specialized manufacturing infrastructure alongside the clinical development of its pipeline, MRM Health is addressing an important future manufacturing and supply requirement for complex live biotherapeutic products and further strengthening the readiness of its programs for pharmaceutical partnerships and commercialization.

Biocodex will invest €15 million over the coming years in a new manufacturing infrastructure dedicated to live biotherapeutic products, including anaerobic manufacturing capabilities at its state-of-the-art pharmaceutical site in Beauvais, France. Biocodex will fund, build, own and operate the facility, while MRM Health will contribute its proprietary anaerobic manufacturing expertise to its design and implementation. The infrastructure will be designed to support the specific manufacturing requirements of products derived from MRM Health’s proprietary CORAL® platform, while also supporting other live biotherapeutic programs.

“Developing next-generation live biotherapeutics into successful medicines requires manufacturing capabilities that are just as sophisticated as the underlying science,” said Dr. Sam Possemiers, Chief Executive Officer of MRM Health. “Together with Biocodex we are establishing a specialized and scalable manufacturing pathway from clinical development to future commercial production. This partnership strengthens the readiness of both our own pipeline and CORAL® programs developed with pharmaceutical partners for future commercialization, bringing us closer to delivering microbiome-based therapeutics to patients.”

“This strategic collaboration strengthens the partnership we began last year with MRM Health,” added Nicolas Coudurier, Chief Executive Officer of Biocodex. “By combining our expertise, we are helping to strengthen European industrial capabilities in the field of live biotherapeutics. This is an important step in supporting the development of these new therapeutic approaches and ultimately enabling patients to benefit from them.”

A platform-enabling partnership supporting multiple MRM programs

The partnership establishes a framework under which Biocodex may provide process development, analytical testing and GMP manufacturing services for individual CORAL® programs under program-specific agreements. MRM Health will have access to the manufacturing infrastructure for its proprietary, partnered and out-licensed CORAL® programs. The non-exclusive nature of the collaboration preserves MRM Health’s flexibility to engage additional or alternative manufacturing partners where appropriate. This flexible partnership provides an additional manufacturing pathway for its lead candidate MH002 and its broader pipeline while reducing the need for its pharmaceutical partners to establish specialized manufacturing pathways independently as programs advance toward commercialization.

Scalable industrial support, from development to commercial supply

MRM Health has developed proprietary expertise in the scalable manufacturing of complex bacterial consortia through its single-process CORAL® production technology. The new infrastructure will build on this proficiency, as well as on the industrial experience of Biocodex, and provide a coordinated pathway for technology transfer, process development, clinical manufacturing and future commercial supply.

The facility will provide flexible manufacturing infrastructure across multiple scales. For MRM Health, it will enable the progression of both MH002 and other pipeline programs from development through later-stage clinical manufacturing and ultimately toward commercial-scale production. Capacity supporting CORAL® programs will expand in line with the clinical and commercial progress of MRM Health’s portfolio. Initial process development and pilot manufacturing activities are expected to begin by 2027, with commercial-scale manufacturing targeted from 2030.

***

About MRM Health

MRM Health is a clinical-stage biotech developing innovative live biotherapeutic products (LBPs) for immune-mediated diseases with high unmet needs. The Company’s lead program, MH002, for inflammatory bowel diseases (IBD), is currently being evaluated in the 204-patient STARFISH-UC Phase 2b study in patients with mild-to-moderate ulcerative colitis, following positive Phase 2a clinical data in ulcerative colitis and pouchitis. MH002 received FDA Fast Track designation in April 2026. MRM Health is expanding its pipeline across other inflammatory diseases and immuno-oncology, leveraging AI-guided discovery and deep expertise in microbiome ecosystem biology. Its CORAL® platform enables the rational design and manufacture of disease-focused microbial consortia with enhanced efficacy and scalability. In September 2025, MRM Health successfully closed a €55 million Series B round led by Biocodex, with strong support from ATHOS, BNP Paribas Fortis Private Equity and existing investors SFPIM, AvH, OMX Europe VF, QBIC II and VIB.

For more information, please follow us on LinkedIn or visit the website at www.mrmhealth.com.

About Biocodex

Biocodex is an independent French pharmaceutical company operating in more than 100 countries through its subsidiaries or partners. As a pioneer in gut microbiota research, the company has made it a central strategic focus, driven by the conviction that this ecosystem plays a key role in overall health and a more holistic approach to care.

The Group develops innovative healthcare solutions across four complementary areas: microbiota, women’s health, rare diseases, and established products addressing everyday health needs (mental health, sleep, pain, etc.). True to its family-owned identity, Biocodex promotes a committed vision of health that combines scientific excellence, a strong industrial base in France, international reach, and corporate social responsibility. This commitment has been recognized with the “Engagé RSE” label – Confirmed level (★★), awarded by AFNOR Certification and recognized across Europe through Responsibility Europe.

Empowering everyone to live fully is Biocodex’s purpose, embodied by its 1,900 employees worldwide.

Contacts

This press release or the information contained therein is not being issued and may not be distributed in the United States of America, Canada, Australia or Japan or any other jurisdiction in which the distribution or release would be unlawful or require registration or any other measure and does not constitute an offer of securities for sale in any country.

PRESS RELEASE | AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR

EvoNext Holdings SA makes available the consolidated financial statements of Ascend Sport Technology AG for the financial year 2025/26

Reinach / Lucerne, Switzerland, 5 November 2026 – As part of the transaction documentation ahead of the upcoming merger, today EvoNext Holdings SA is making available the unaudited consolidated financial statements of Ascend Sport Technology AG (“Ascend”) for the financial year ended 30 June 2026, together with comparative figures for the financial year ended 30 June 2025.

Ascend reports the following unaudited key figures¹:

¹ Net revenues, EBITDA, depreciation, amortization, EBIT and net profit relate to the financial years from 1 July to 30 June (FY 2025/26 and FY 2024/25); all balance sheet items are stated as at 30 June 2026 and 30 June 2025, respectively.
² Net working capital comprises trade receivables, other current receivables, inventories and accrued income and prepaid expenses, less trade payables, other current liabilities, current provisions and deferred revenue and accrued expenses. It excludes cash and cash equivalents, securities, financial liabilities and non-current provisions.
³ Financial liabilities comprise current and non-current financial liabilities (FY 2025/26: CHF 2.6 million current, nil non-current; FY 2024/25: CHF 2.1 million current, CHF 1.9 million non-current).

All figures are unaudited.

The complete unaudited consolidated financial statements of Ascend for the financial year 2025/26 (without notes), comprising the consolidated balance sheet, income statement and cash flow statement, are available here.

EvoNext Holdings SA and Ascend Sport Technology AG signed the merger agreement on 1 November 2026. The Swiss sports technology holding company Ascend is expected to become, subject to certain conditions including the approval of the shareholders of both companies, a publicly listed entity through a merger into EvoNext with its existing listing on SIX Swiss Exchange.

Contact for investors and media

EvoNext Holdings SA

investors@evonextholdings.com

susanne.muehlemann@lemongrass.agency / +41 79 223 70 81

Disclaimer

This publication constitutes neither an offer to sell nor a solicitation to buy securities of EvoNext Holdings SA and it does not constitute a prospectus or a similar notice within the meaning of articles 35 et seqq. or 69 of the Swiss Financial Services Act. Any offer and listing of any securities in EvoNext Holdings SA (“Securities”) will be made solely by means of, and on the basis of, a prospectus which is to be published. An investment decision regarding any publicly offered Securities should only be made on the basis of such prospectus. The prospectus will be available free of charge from the accompanying bank.

This publication may contain specific forward-looking statements, e.g., statements including terms like “believe”, “assume”, “expect”, “forecast”, “project”, “may”, “could”, “might”, “will” or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of EvoNext Holdings SA or Ascend Sport Technology AG and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties, readers should not rely on forward-looking statements. EvoNext Holdings SA assumes no responsibility to update forward-looking statements or to adapt them to future events or developments. Moreover, financial information contained in this publication may be preliminary and unaudited.

This communication is being distributed only to, and is directed only at (i) persons outside the United Kingdom, (ii) persons who have professional experience in matters relating to investments falling within article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Order”) or (iii) high net worth entities, and other persons to whom it may otherwise lawfully be communicated, falling within Article 49(2) of the Order (all such persons together being referred to as “Relevant Persons”). Any potential investment or investment activity to which this communication relates will be available only to Relevant Persons and will be engaged in only with Relevant Persons. Any person who is not a Relevant Person must not act or rely on this communication or any of its contents.

This communication does not constitute an “offer of securities to the public” within the meaning of Regulation 2017/1129 of the European Union (the “Prospectus Regulation”) of the securities referred to in it (the “Securities”) in any member state of the European Economic Area (the “EEA”) or, in the United Kingdom (“UK”), the UK Public Offers and Admissions to Trading Regulations 2024 (the “POATRs”). Any placements of any Securities to persons in the EEA or the UK will be made pursuant to an exemption under the Prospectus Regulation or the POATRs (as applicable), as implemented in member states of the EEA or the UK, from the requirement to produce a prospectus for offers of Securities.

Any securities referred to herein have not been and will not be registered under the US Securities Act of 1933, as amended (the “Securities Act”), and may not be offered or sold in the United States or to US persons (as such term is defined in Regulation S under the Securities Act) unless the securities are registered under the Securities Act, or an exemption from the registration requirements of the Securities Act is available. The issuer of the securities has not registered, and does not intend to register, any portion of any potential placements in the United States, and does not intend to conduct a public offer of securities in the United States.

This communication is not for distribution in the United States, Canada, Australia, Japan or any other jurisdiction into which the same would be unlawful and does not constitute an offer of securities for sale in such countries. This communication does not constitute an offer to sell, or the solicitation of an offer to buy, securities in any jurisdiction in which is unlawful to do so.

Evotec Reports Third Quarter and Nine-Month 2026 Results: Building Growth Momentum Toward 2030 Goals
 

• Financial performance: Q3 and nine-month Group revenue of €164.9 m and €465.0 m, respectively (Q3: €164.2 m, 9M: €477.4 m at CER); adj. Group EBITDA of -€1.6 m and -€44.3 m, respectively (Q3: -€1.7 m, 9M: -€39.1 m at CER)
• Robust commercial momentum: Net sales* in D&PD base business increased 24% vs. 9M 2025 accompanied by continued positive development across key commercial indicators.
• FY 2026 guidance reaffirmed: Expected Group revenue of €570 to €610 m (€595 to €635 m CER) and adj. Group EBITDA of -€105 to -€70 m (-€90 to -€60 m CER).
• 2030 framework further detailed: Around €1 billion in Group revenue by 2030 with further upside potential; adjusted EBITDA margin of 20% at YE 2028 and above 20% at YE 2030.
• Continued progress across differentiated platforms: Evotec confirms selection by Vertex Pharmaceuticals for commercial manufacturing of povetacicept; advancement of orthopoxvirus antibody program into Phase 1 in collaboration with DoW; new collaborations with Plectonic and Odyssey Therapeutics broaden partnered innovation activities.
• Horizon transformation ahead of plan: More than 20% of €75 million annual run-rate savings target delivered by September, already within 20-30% contribution planned for full-year 2026; workforce and footprint measures on track.
• Leadership Update: Dr. Joanna Holbrook appointed Chief Scientific Officer, strengthening Evotec’s focus on scientific excellence, platform differentiation and partnered innovation.
• Investor and analyst webcast and conference call today: 2 p.m. CET / 1 p.m. GMT / 8 a.m. EST; registration and webcast details below.

Hamburg, Germany, November 5, 2026 – Evotec SE (NASDAQ: EVO; Frankfurt Prime Standard: EVT) today announced financial results for the third quarter and first nine months of 2026, provided an update on the implementation of its Horizon transformation and outlined its strategic and financial ambition for 2030.

Dr. Christian Wojczewski, Chief Executive Officer of Evotec, said:

“During the third quarter and first nine months of 2026, we made encouraging progress across several areas that are important to Evotec’s future development. Commercial momentum remained solid, Horizon is delivering ahead of plan and Just – Evotec Biologics is advancing toward commercial-scale manufacturing. Implementation of our strategy is gaining momentum and is increasingly reflected in our performance. Group revenue reached €164.9 million in the third quarter, well above the first two quarters of the year, supported by a robust contribution from the D&PD base business.

We also successfully launched several new partnerships based on our technology platforms. Recent examples include Plectonic, where we are exploring new T-cell-engaging approaches in solid tumors. With Odyssey Therapeutics, our AI-enabled discovery platform is supporting drug discovery in autoimmune and inflammatory diseases. These collaborations illustrate how we are applying our differentiated scientific capabilities in new areas, creating exciting opportunities with partners.”

Selected Business Highlights

Evotec made strong progress across its differentiated platforms and strategic partnerships:

Just – Evotec Biologics (JEB)

• Vertex Pharmaceuticals – Commercial Manufacturing of Povetacicept: Evotec confirms that Just – Evotec Biologics has been selected by Vertex Pharmaceuticals for commercial manufacturing of povetacicept at its J.POD® Redmond facility. The agreement marks an important step in the evolution of JEB’s continuous manufacturing platform toward commercial readiness. Evotec is highly confident in its ability to fulfill its commercial manufacturing and supply commitments to Vertex.
• DoW Orthopoxvirus Program – JST-018 Phase 1 Initiated: In September 2026, Evotec announced the initiation of a Phase 1 clinical trial evaluating JST-018, an investigational antibody cocktail developed by Just – Evotec Biologics under the U.S. Department of War’s Accelerated Antibodies Program. Just – Evotec Biologics advanced the program from antibody sequence selection through preclinical development, process development, regulatory submission and cGMP manufacture of clinical trial materials.

Discovery and Preclinical Development (D&PD)

• Jazz Pharmaceuticals – Phase 1 Initiated: Jazz Pharmaceuticals has initiated a Phase 1 clinical trial of a candidate for the potential treatment of narcolepsy and idiopathic hypersomnia. The candidate was discovered through Jazz’s sleep disorders collaboration with Evotec. Evotec combined its proprietary virtual screening and generative AI platforms with rational design to identify novel leads, subsequently optimized with the aid of cryoEM and molecular dynamics simulations. Evotec is eligible to milestone payments.
• Plectonic Research Collaboration – Novel Immunotherapy Approaches: In September 2026, Evotec and Plectonic entered a research collaboration combining Evotec’s BiTco platform with Plectonic’s LOGIBODY® technology to explore new T-cell-engaging approaches for solid tumors. The collaboration will generate preclinical proof-of-concept data to evaluate whether the combined technologies can improve the precision and potency of these approaches.
• Odyssey Therapeutics Research Collaboration – AI-Enabled Drug Discovery: In August 2026, Evotec entered an R&D collaboration combining Odyssey’s expertise in autoimmune and inflammatory diseases with Evotec’s AI-enabled discovery platform, advanced screening capabilities and proprietary compound libraries. Evotec is eligible to receive milestone payments based on the successful delivery of validated starting points for drug discovery across multiple targets.

Commercial Execution

Commercial momentum and execution continued to strengthen during the third quarter of 2026. Net sales in the D&PD base business, comprising stand alone services and integrated programs, increased by 24% year-on-year in the first nine months. Positive trends extended across the commercial funnel, with growth in the customer base, higher proposal activity and faster proposal turnaround. The strategic partnership opportunity pipeline also continued to expand.

Horizon Transformation

Horizon is progressing ahead of plan, with structural measures translating into measurable financial and operational improvements. By the end of September, Evotec had delivered more than 20% of the €75 million in annual run-rate savings targeted by the end of 2027, already within the 20-30% contribution planned for full-year 2026. Approximately half of the planned workforce reductions have been implemented. Footprint consolidation is advancing, with three of the four site closures expected to be completed by year-end and the fourth in the first quarter of 2027. Alongside these measures, Evotec is concentrating scientific capabilities in focused Centers of Excellence and strengthening commercial execution to build a more efficient operating model and support sustainable profitability. Evotec expects to deliver the transformation program in full and on schedule by the end of 2027.

Leadership Update

Chief Scientific Officer: Dr. Joanna Holbrook

As announced on October 15, 2026, Dr. Joanna Holbrook has succeeded Dr. Cord Dohrmann as Chief Scientific Officer and member of Evotec’s Management Board, effective November 1, 2026.

Bringing more than 25 years of experience as a scientist and R&D leader, Dr. Holbrook will lead Evotec’s global scientific strategy, with a focus on strengthening scientific differentiation across discovery and development services, technology platforms and proprietary innovation. Her expertise across data, AI and novel technologies will support Evotec in building integrated solutions to important challenges in drug discovery and helping customers and partners discover and develop new medicines faster and with a greater probability of success.

2030 Mid-Range Framework – Building a Structurally Stronger Business

Evotec is building a more balanced and profitable business, drawing on the distinctive strengths of its component parts. The 2030 framework calls for around €1 billion in Group revenue by 2030, with potential for additional upside. It includes an adjusted EBITDA margin of 20% by the end of 2028, rising above 20% by the end of 2030.

The D&PD base business, comprising standalone services and integrated programs, is expected to contribute approximately 40% of Group revenue in 2030. Growth is expected to be supported by continued market recovery, commercial investments and Evotec’s differentiated service offerings.

D&PD strategic partnerships and innovation-related activities are expected to contribute approximately 20% at above-average margins. This contribution incorporates risk-adjusted assumptions regarding program progression and associated revenue, while future royalty income is not included. Performance exceeding these assumptions could provide additional revenue upside beyond the approximately €1 billion framework.

Just – Evotec Biologics is expected to contribute approximately 40% of Group revenue as the business scales, supported by capacity expansion, licensing income and future, contractually agreed royalties.

Profitability is expected to benefit from greater contribution from scalable, higher-margin activities, operating leverage and continued cost efficiency.

Financial Results

Claire Hinshelwood, Chief Financial Officer of Evotec, said:

“Our strong third-quarter performance reflects the positive impact of the commercial investments and Horizon initiatives launched earlier this year. We are now seeing these efforts translate into improved profitability and operational momentum. Looking ahead, our focus remains on converting this momentum into sustainable revenue growth and stronger cash generation, while maintaining disciplined cost management, liquidity oversight, and capital allocation. Today, we are pleased to provide greater transparency into our 2030 financial framework, including the business mix and operational drivers that support a high-quality, diversified platform for future earnings growth.”

Group Financials

For the third quarter of 2026, Group revenue amounted to €164.9 million (€164.2 million CER), essentially unchanged from €163.9 million in the prior-year quarter. Adjusted Group EBITDA was -€1.6 million (-€1.7 million CER), versus -€15.0 million in the same prior‑year period, reflecting a marked year-on-year improvement of 89.1% primarily attributable to lower cost of revenue.

For the nine months ended September 30, 2026, Group revenue amounted to €465.0 million (€477.4 million CER), compared with €535.1 million in the prior-year period, reflecting a 13.1% decline. Consistent with the Company’s focus on cost discipline, R&D expenses amounted to €29.7 million or 6.4% of total Group revenue, compared with €42.3 million or 7.9% of total Group revenue in the prior-year period. Adjusted Group EBITDA decreased to
-€44.3 million (-€39.1 million CER), down from -€16.9 million for the nine months ending September 30, 2025. The decrease in revenue was partially offset by lower cost of revenue.

Evotec closed the third quarter of 2026 with a liquidity position of €400.9 million, reflecting a net debt position.

Segment Financials (excluding intersegment revenue)

Discovery and Preclinical Development (D&PD)

For the third quarter of 2026, revenue for Discovery & Preclinical Development totaled €120.1 million (€119.6 million CER), representing a modest year-on-year decline of 2.3%. Adjusted EBITDA for the quarter improved to
-€1.0 million (-€1.4 million CER), compared with -€9.5 million in the third quarter of 2025.

For the first nine months of 2026, revenue totaled €348.0 million (€355.5 million CER), compared with
€391.9 million in the prior-year period. The 11.2% year-on-year decrease was primarily driven by lower sales-to-revenue conversion across all D&PD segments. Adjusted EBITDA for the segment was -€25.5 million
(-€19.8 million CER), compared with -€18.8 million in the prior-year period. The decrease was primarily driven by lower revenue and partially offset by a lower cost base across cost of revenue, R&D and SG&A.

Just – Evotec Biologics (JEB)

Third quarter 2026 revenue at Just – Evotec Biologics totaled €44.8 million (€44.6 million CER), representing a 9.4% increase compared with the prior-year period. Adjusted EBITDA reached -€0.6 million (-€0.3 million CER), compared with -€5.5 million in the prior-year period.

For the first nine months of 2026, revenue totaled €117.1 million (€121.9 million CER), compared with
€143.2 million in the same period in 2025. The 18.3% year-on-year decrease was primarily driven by the $25 million Sandoz license sale recognized in Q1 2025 and delayed program activities. Adjusted EBITDA amounted to
-€18.8 million (-€19.3 million CER), compared with an Adjusted EBITDA of €1.9 million in the prior-year period.

Reaffirming Full-Year 2026 Guidance

Evotec confirms its full-year 2026 outlook for Group revenue of approximately €570 to €610 million (€595 to
€635 million CER) and adjusted Group EBITDA of approximately -€105 to -€70 million (-€90 to -€60 million CER).

Strategic Review

The strategic evaluation announced in connection with the Company’s first quarter 2026 results on May 6, 2026, remains ongoing and continues alongside the implementation of the Horizon transformation program. Additional details regarding the review are available in the Company’s Q1 2026 results announcement.

 
Webcast Details

Evotec will host a webcast and conference call today at 2 p.m. CET / 1 p.m. GMT / 8 a.m. EST.

To join the audio webcast and to access the presentation slides, please register via this link.

The on-demand replay of the webcast will be available under the same link after the event and on our website.

Conference Call Details

To join the conference call, please pre-register via this link. You will receive a confirmation email with dedicated dial-in details such as telephone number, access code and PIN to access the call.
A simultaneous slide presentation for participants dialing in via phone is available under this link.

 
*Net Sales: includes signed work orders, positive change orders and negative change orders
 

About Evotec SE

Evotec is a life science company pioneering the future of drug discovery and development. By integrating breakthrough science with AI-driven innovation and advanced technologies, Evotec accelerates the journey from concept to cure with greater speed, intelligence and precision. The company’s expertise spans small molecules, biologics, cell therapies and associated modalities, supported by proprietary platforms including Molecular Patient Databases, PanOmics and induced pluripotent stem cell-based disease modeling. Through flexible partnering models tailored to customers’ needs, Evotec works with all Top 20 pharmaceutical companies, more than 800 biotechnology companies, academic institutions and other healthcare stakeholders. Evotec’s offerings range from standalone services to fully integrated research and development programs and long-term strategic partnerships, combining scientific excellence with operational agility. Through Just – Evotec Biologics, the company is redefining biologics development and manufacturing to improve accessibility and affordability. With a portfolio of more than 100 proprietary research and development assets, most of which are co-owned, Evotec focuses on key therapeutic areas including oncology, cardiovascular and metabolic diseases, neurology and immunology. Evotec’s global team of around 4,500 experts operates from sites in Europe and the United States, providing complementary technologies and services through a network of synergistic centers of excellence. Learn more at www.evotec.com and follow Evotec on LinkedIn and X at @Evotec.

Forward-Looking Statements

This announcement contains forward-looking statements concerning future events, including Evotec’s financial results, full-year 2026 outlook, expected commercial conversion, anticipated strategic partnership and milestone contributions, Horizon implementation, expected cost savings, liquidity, financial flexibility and future business performance. Words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “should,” “target,” “would” and variations of these words and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based on information available to Evotec and on expectations and assumptions considered reasonable by the company at the time the statements were made. No assurance can be given that these expectations will prove correct. Forward-looking statements involve known and unknown risks and are based on assumptions and estimates that are inherently subject to significant uncertainties and contingencies, many of which are beyond Evotec’s control. Evotec expressly disclaims any obligation or undertaking to publicly update or revise any forward-looking statements contained in this announcement to reflect changes in expectations, events, conditions or circumstances, except as required by applicable law.

Investor Relations and Media Contact

Dr. Sarah Fakih
EVP, Head of Global Communications & Investor Relations
Sarah.Fakih@evotec.com

Key figures of consolidated income statement & segment information
 

Media Release – ad hoc announcement pursuant to Art. 53 LR

Definitive end result of the public tender offer of Samsung Biologics Co., Ltd.

Baar, Switzerland, 5 November 2026 – Samsung Biologics Co., Ltd. (“Samsung Biologics”), through its direct subsidiary Samsung Peptide AG (“Samsung Peptide”), today published the definitive end result of its public tender offer (the “Offer”) for all publicly held registered shares of PolyPeptide Group AG (“PolyPeptide”) (SIX: PPGN).

The additional acceptance period of the Offer ended on 30 October 2026, at 4:00 p.m. Swiss time. According to the definitive end result as published by Samsung Peptide,

• the participation of Samsung Peptide and the persons acting in concert with Samsung Peptide amounts to 32,458,892 PolyPeptide shares in aggregate, corresponding to 97.99% of the issued share capital and voting rights of PolyPeptide (participation rate); and
• 32,350,302 PolyPeptide shares were tendered into the Offer until the end of the additional acceptance period of the Offer, corresponding to 97.66% of the issued share capital and voting rights of PolyPeptide and 97.98% of all PolyPeptide shares to which the Offer relates (success rate).

The definitive end result that has been published today by Samsung Peptide is available at https://samsungbiologics.com/offer.

According to the definitive end result as published by Samsung Peptide, the Offer remains subject to certain remaining Offer conditions, including the receipt of regulatory approvals in certain jurisdictions.

In its provisional end result published on 2 November 2026, Samsung postponed the settlement of the Offer in accordance with section B.7.3 (Period for which the Offer Conditions are in Force and Effect and Deferral) of the offer prospectus of Samsung Peptide dated 31 August 2026 (the “Offer Prospectus”). Samsung confirmed in its provisional and definitive end result that based on the current understanding of the regulatory approval procedures in various countries (see the Offer condition pursuant to section B.7.1(b) (Merger and FDI Clearances) of the Offer Prospectus), the transaction is currently expected to be completed towards the end of 2026 or in Q1 2027.

According to the definitive end result as published by Samsung Peptide, Samsung Peptide intends to pursue a squeeze-out of any remaining public shareholders and to apply to SIX Exchange Regulation for the delisting of the PolyPeptide shares following the settlement of the Offer.

Contact

PolyPeptide Group AG
Strategic Marketing and Corporate Communications
Laura Rosso
mediateam@polypeptide.com
T: +41 43 502 0580

PolyPeptide Group AG
Finance / Investor Relations
Tim Brandl
investorrelations@polypeptide.com
T: +41 43 502 0580 

About PolyPeptide

PolyPeptide Group AG and its consolidated subsidiaries (“PolyPeptide”) is a specialized Contract Development & Manufacturing Organization (CDMO) for peptide-based active pharmaceutical ingredients. By supporting its customers mainly in pharma and biotech, it contributes to the health of millions of patients across the world. PolyPeptide serves a fast-growing market, offering products and services from pre-pre-clinical to commercial stages. Its broad portfolio reflects the opportunities in drug therapies across areas and with significant exposure to metabolic diseases, including GLP-1. Dating back to 1952, PolyPeptide today runs a global network of six GMP-certified facilities in Europe, the U.S. and India. PolyPeptide’s shares (SIX: PPGN) are listed on SIX Swiss Exchange. For more information, please visit polypeptide.com.

@PolyPeptide — follow us on LinkedIn

About Samsung Peptide and Samsung Biologics

Samsung Peptide is a direct subsidiary of Samsung Biologics. Samsung Biologics and PolyPeptide have concluded a transaction agreement on 17 July 2026 regarding the Offer. Samsung Peptide is acting as the formal offeror of the Offer. Samsung Biologics (KRX: 207940.KS) is a leading Contract Development & Manufacturing Organization (CDMO), offering end-to-end integrated services that range from late discovery to commercial manufacturing. With a combined biomanufacturing capacity of 785,000 liters across Bio Campus I and II in Korea, and 60,000 from the manufacturing facility in Rockville, Maryland, U.S., Samsung Biologics holds total global manufacturing capacity of 845,000 liters. Samsung Biologics has also secured land for Bio Campus III, laying the groundwork for future capacity expansion to support next-generation therapies and emerging modalities. Samsung Biologics leverages cutting-edge technologies and expertise to advance diverse modalities, including multispecific antibodies, fusion proteins, antibody-drug conjugates, and mRNA therapeutics. By implementing the ExellenS™ framework across its manufacturing network with standardized designs, unified processes, and advanced digitalization, Samsung Biologics ensures plant equivalency and speed for manufacturing continuity. Samsung Biologics’ global manufacturing and commercial network spans Korea, the U.S., Europe, and Japan. Samsung Biologics continues to invest in new capabilities to maximize operational and quality excellence, ensuring flexibility and agility for clients. Samsung Biologics is committed to the on-time, in-full delivery of safe, high-quality biomedicines, as well as to making sustainable business decisions for the betterment of society and global health. For more information, please visit https://samsungbiologics.com.

Legal Notice and Disclaimer

No Offer / Offer Restrictions

The information in this media release is for informational purposes only. It does not constitute, or form part of, any offer or invitation to purchase, sell, exchange or issue, or any solicitation of an offer to sell, purchase, exchange or subscribe to, any registered shares or other securities of PolyPeptide or any other person, nor shall it form the basis of, or be relied upon in connection with, any contract in relation thereto. This media release is not part of Samsung Peptide’s publication of the definitive end result of the Offer or any other publication, communication or other documentation of Samsung Peptide or Samsung Biologics relating to the Offer, including without limitation the Offer Prospectus (the “Offer Documentation”). Terms and conditions of the Offer have been published by Samsung Peptide and Samsung Biologics in the Offer Documentation. Shareholders of PolyPeptide are urged to read the Offer Documentation, which is available at https://samsungbiologics.com/offer.

This announcement is not for publication, release or distribution in any country or jurisdiction in which it would be considered unlawful or otherwise violate any applicable laws or regulations, or which would require Samsung Peptide or Samsung Biologics to change or amend the terms or conditions of the Offer in any way, to make an additional filing with any governmental, regulatory or other authority or take additional action in relation to the Offer. Full Offer restrictions can be found in Samsung Peptide’s Offer Prospectus at https://samsungbiologics.com/offer.

Forward-looking Information and Statements

This media release has been prepared by PolyPeptide and includes forward-looking information and statements concerning the outlook for the Group’s business. These statements are based on current expectations, estimates and projections about the factors that may affect the Group’s future performance. These expectations, estimates and projections are generally identifiable by statements containing words such as ‘expects’, ‘believes’, ‘estimates’, ‘targets’, ‘plans’, ‘projects’, ‘outlook’ or similar expressions. There are numerous risks, uncertainties and other factors, many of which are beyond PolyPeptide’s control, that could cause the group’s actual results to differ materially from the forward-looking information and statements made in this media release and that could affect the group’s ability to achieve its stated targets. Although PolyPeptide believes that its expectations reflected in any such forward-looking statement are based upon reasonable assumptions, it can give no assurance that those expectations will be achieved.

Except as otherwise required by law, PolyPeptide disclaims any intention or obligation to update any forward-looking statements as a result of developments.

Ad hoc announcement pursuant to Art. 53 LR

Fribourg, 5 November 2026

AEVIS VICTORIA SA: Continued Revenue Growth in the Third Quarter of 2026

Consolidated gross revenue up 8.2% (7.7% organic), driven by healthcare. Net revenue stable at CHF 789.4 million, up 0.6% on a like-for-like basis.

In the first nine months of 2026, AEVIS VICTORIA SA generated consolidated gross revenue of CHF 972.7 million (9M 2025: CHF 899.2 million), an increase of 8.2%. Net revenue, the Group’s key reference metric, amounted to CHF 789.4 million (9M 2025: CHF 789.9 million), stable (-0.1%). Excluding scope effects and the sale of apartments in Zermatt recognized in 2025, net revenue grew by 0.6%.

The growth in gross revenue mainly reflects the presentation of fees of independent physicians at Swiss Medical Network. These fees are recognized in gross revenue and then passed through as third-party services; they amounted to CHF 183.3 million (9M 2025: CHF 109.3 million). Net revenue, which excludes these fees, is the Group’s key reference metric.

Healthcare: Solid Growth and Integration of Radiologia Ticino
Swiss Medical Network, which operates 18 clinics and hospitals and 80 outpatient centers, generated gross revenue of CHF 804.2 million (9M 2025: CHF 722.6 million), up 11.3% (10.7% organic). Net revenue rose 1.2% to CHF 620.9 million (9M 2025: CHF 613.3 million). On a constant scope basis, i.e., excluding Radiologia Ticino, which has been consolidated since January 1, 2026, growth was 0.5%, or 1.6% excluding the impact of the restructuring of Privatklinik Lindberg.

The hospital business posted gross revenue of CHF 632.9 million (+12.2%) and net revenue of CHF 466.3 million, a slight decrease of 0.5% (+0.8% excluding Privatklinik Lindberg). The outpatient business recorded gross revenue of CHF 91.6 million (+6.2%) and net revenue of CHF 80.0 million (+5.2%), of which CHF 4.4 million was contributed by Radiologia Ticino.

The transfer of Privatklinik Lindberg’s medical activities to the Bethanien (Zurich) and Belair (Schaffhausen) clinics has been completed; Kantonsspital Winterthur took over the premises on October 1, 2026. The full positive impact of this measure will be felt from fiscal year 2027. The continuous improvement in profitability over the first nine months, combined with the restructuring measures implemented, provides a solid foundation for the remainder of fiscal year 2026 and for 2027.

Hospitality: Higher Average Rates and Acceleration at Period-End
MRH Switzerland AG, the Group’s hospitality division managed by Michel Reybier Hospitality, generated revenue of CHF 159.5 million (9M 2025: CHF 157.4 million), up 1.3%, entirely organic. The average daily rate rose 5.4% to CHF 607 and revenue per available room (RevPAR) 5.1% to CHF 348, with occupancy virtually stable at 57.4%. Momentum picked up significantly toward the end of the period, with September revenue up 9.2%.

Real Estate: Rental Income Up 12.2%
Swiss Hotel Properties SA generated revenue of CHF 29.5 million (9M 2025: CHF 36.1 million). The decline reflects the comparison base, which included CHF 10.1 million in gains on the sale of apartments in Zermatt (CHF 0.3 million in 2026). Rental income rose 12.2% to CHF 29.2 million.

For further information
Media and Investor Relations: c/o Dynamics Group, Zurich
Marion Schihin, msc@dynamicsgroup.ch, +41 79 705 88 15

AEVIS VICTORIA SA – Investing for a better life
AEVIS VICTORIA SA invests in healthcare, hospitality & lifestyle and infrastructure. AEVIS’s main shareholdings are Swiss Medical Network Holding SA (76.3%, directly and indirectly), the only Swiss private network of hospitals present in the country’s three main language regions, MRH Switzerland AG, a luxury hotel group managing eleven hotels in Switzerland and abroad, Infracore SA (22.6%, directly and indirectly), a listed real estate company (INFRAC.SW) dedicated to healthcare-related infrastructure, Swiss Hotel Properties SA, a hospitality real estate division, and NESCENS SA, a brand dedicated to better aging. AEVIS is listed on the Swiss Reporting Standard of the SIX Swiss Exchange (AEVS.SW). www.aevis.com.

Topadur’s Phase 2a Trial of TOP-N53 for Systemic Sclerosis-Associated Digital Ulcers Advances to Next Dose Levels

Schlieren-Zurich, Switzerland, 05 November 2026 – Topadur Pharma AG, a Swiss clinical-stage biopharmaceutical company, today announced that the Safety Review Committee of its Phase 2a trial has recommended progression to the next planned dose levels. The trial is evaluating lead candidate TOP-N53 for the treatment of systemic sclerosis-associated digital ulcers. The recommendation follows a review of safety data and the completion of the first patient cohort. No protocol-defined stopping criteria were met, and no serious adverse drug reactions were reported.

TOP-N53 is a novel, bifunctional topical therapeutic candidate designed to improve microcirculation and support tissue repair. By combining nitric oxide (NO) release and phosphodiesterase-5 (PDE5) inhibition in a single small molecule, TOP-N53 aims to enhance cGMP signaling directly at the site of application. Its clinical development builds on a first-in-human Phase 1 study in healthy volunteers, which demonstrated favorable tolerability and increased local skin perfusion following subcutaneous administration. TOP-N53 holds orphan drug designation in both the US and the European Union for the treatment of systemic sclerosis-associated digital ulcers. The ongoing open-label, vehicle-controlled Phase 2a trial (NCT06954597), conducted in Switzerland and France, evaluates the safety and tolerability of ascending doses of TOP-N53 applied topically to digital ulcers in patients with systemic sclerosis.

“TOP-N53 is a key program for Topadur as we investigate the potential of locally acting therapies to address diseases with significant unmet medical needs,” said PD Dr. Matthias Schäfer, CEO of Topadur Pharma AG. “With the Safety Review Committee’s recommendation to proceed to the next dose levels, we have reached an important milestone in the clinical development of TOP-N53. We are grateful to the patients and clinical teams whose participation and dedication make it possible to move this clinical trial forward.”

Systemic sclerosis is a rare autoimmune disease characterized by damage to small blood vessels and fibrosis of the skin and internal organs. About half of patients develop digital ulcers, painful wounds on the fingers that are often slow to heal and prone to recurrence. Treatment options for existing ulcers remain limited, and current drug treatments act systemically. A 2025 consensus report by the World Scleroderma Foundation[i] highlights the significant unmet medical need for local treatment strategies for digital ulcers.

“Even a single digital ulcer can cause significant pain and severely affect a patient’s daily life, making activities as simple as buttoning a shirt or holding a pen difficult,” said Prof. Marie-Elise Truchetet, Department of Rheumatology, CHU de Bordeaux, France, and Principal Investigator at the Bordeaux study site. “There is a clear need for new local treatment options. Evaluating the safety and tolerability of TOP-N53 at increasing doses is an important step towards understanding its potential for patients with digital ulcers.”

The trial is part of a start-up innovation project supported by Innosuisse. Recruitment for the second cohort is scheduled to begin in November at six clinical centers in Switzerland and France, coinciding with the colder months, when new digital ulcers occur more frequently.

Contacts

Topadur Pharma AG
Yoshita Bhide
Media Communications
+41 44 755 44 66
yoshita.bhide@topadur.com

Media inquiries:
MC Services
Anne Hennecke, Julia Bittner
+49 89 210 2280
contact@mc-services.eu
 

Disclaimer

TOP-N53 is an investigational product and has not been approved by Swissmedic, the European Commission, the US Food and Drug Administration or any other regulatory authority. Its safety and efficacy have not been established. Observations from the first cohort are preliminary, based on a small number of patients treated at the lowest dose in an open-label setting, and may not predict results at higher doses or of the completed trial. This press release is intended for media and investors; it does not promote any medicinal product, provide medical advice or invite participation in a clinical trial.

This communication does not constitute an offer or invitation to subscribe for or purchase any securities of Topadur Pharma AG. This publication contains forward-looking statements and assessments or intentions concerning the company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the company to be materially different from those expressed or implied by such statements. Readers should therefore not place reliance on these statements, particularly not in connection with any contract or investment decision. The company disclaims any obligation to update these forward-looking statements, assessments or intentions.

^[i] Campochiaro C, et al. “Recommendations for the local management of digital ulcers in systemic sclerosis: A report from the World Scleroderma Foundation (WSF) ‘Ad hoc committee’.” J Scleroderma Relat Disord 2025;10(3):276–284. https://doi.org/10.1177/23971983251339821

Viromed Medical AG Receives Approval for ViroCAP® med in Turkey and Announces Further Operational Progress

Rellingen, November 4, 2026 – Viromed Medical AG (“Viromed”; ISIN: DE000A3MQR65), a medical technology company and pioneer of cold plasma technology, has received approval in Turkey for its medical device ViroCAP® med (MDR Class IIa). The product is now approved for medical applications on the Turkish market, in particular for the treatment of open wounds and intraoperative use.

Uwe Perbandt, CEO of Viromed Medical AG: “The approval of ViroCAP® med in Turkey is a significant success for our international market development. Following the registration of ViroCAP® derma with the ÜTS (National Medical Device Tracking System) in the summer, we have already received approval for ViroCAP® med, which we had expected no earlier than February or March 2027. This marks another important milestone for the commercial launch of our ViroCAP® technology in a healthcare market that is strategically important for us.”

Viromed already has binding minimum orders for 7,000 ViroCAP® derma/med devices through the end of 2028 for the Turkish market. Deliveries will be made on the basis of the approval now granted.

The required process for reimbursement by Turkish health insurers is already running in parallel. With this approval, Viromed continues its international expansion strategy and lays the foundation for the further development of the Turkish market.

ViroCAP® med is designed for professional use by qualified medical personnel and supports the treatment of open wounds as well as intraoperative use of cold atmospheric plasma. The application is contactless and mobile. Each application is planned to last one to two minutes, while skin temperature remains below 40 degrees Celsius.

Additional Local Approval Procedures Initiated

In parallel, Viromed together with its partner Umeco has started the approval process for ViroCAP® med in additional Asian countries. A prerequisite for this was likewise the prior approval of the product as an MDR Class IIa medical device in the EU. Outside the EU, a local approval in each target country is required, which is being pursued together with the distribution partners.

First Reimbursement by a Health Insurer – Selective Contract in Lower Saxony

Viromed has also achieved its first reimbursement of ViroCAP® by a statutory health insurer. A selective contract was concluded with a health insurer in Lower Saxony for an indication in the intensive care area: the treatment of patients with a left ventricular assist device (LVAD). The focus is on preventing infections at the driveline exit site.

Viromed is also in advanced discussions for further selective contracts with health insurers in three additional German federal states.

Further Studies

In November, a successfully completed retrospective study on the prevention of postoperative wound infections will be published. In addition, Viromed is starting a randomized study on the use of ViroCAP® in LVAD patients as well as a further study on the use of the technology in the field of heart valves.

About Viromed Medical AG

Viromed Medical AG specializes in the development, manufacture and distribution of medical products. The operating business of the company, which has been listed on the stock exchange since October 2022, focuses on the distribution of innovative cold plasma technology for medical applications via its wholly owned subsidiary Viromed Medical GmbH. Viromed can draw on a broad customer base in the DACH region and beyond. Viromed is pursuing the goal of further advancing the use of cold plasma technology in medicine in the coming years and realizing the corresponding growth potential.

www.viromed-medical-ag.de

Contact Viromed

E-Mail: kontakt@viromed-medical.de
 

Press contact

E-mail: viromed@kirchhoff.de

PRESS RELEASE

Heidelberg Pharma to Present New Clinical Data on its ATAC Candidates at the ASH Annual Meeting 2026

Ladenburg, Germany, 4 November 2026 – Heidelberg Pharma AG (FSE: HPHA), a clinical stage company developing innovative Antibody Drug Conjugates (ADCs), will present new data from its Phase I/IIa clinical study with its lead Amanitin-based ADC candidate, pamlectabart tismanitin (HDP-101), in an oral presentation, as well as data from its second clinical candidate, HDP-102, during the poster abstract session of the 68^th Annual Meeting of the American Society of Hematology (ASH), being held in New Orleans, USA, from 12 to 15 December 2026.

Details of the oral presentation (HDP-101):

Presentation title: First-in-human phase 1/2a study of pamlectabart tismanitin (HDP-101), an amanitin-based BCMA-targeting antibody-drug conjugate (ADC): Recommended phase 2 dose (RP2D) selection and preliminary antitumor activity in relapsed/refractory multiple myeloma (RRMM)

Pamlectabart tismanitin is an anti-BCMA antibody-Amanitin drug conjugate for the treatment of relapsed or refractory multiple myeloma (RRMM), a bone marrow cancer with a high unmet medical need. Phase I of the trial was a dose-escalation study to determine a dose level of the candidate for the Phase IIa expansion part of the study.

The Phase I part of the study included ten patient cohorts and was completed in April 2026, and the recommended dose for the Phase IIa expansion part (Recommended Phase 2 Dose; RP2D) was determined. The Phase IIa is progressing as planned.

Pamlectabart tismanitin demonstrated consistent clinical activity with a favorable safety profile in heavily pretreated RRMM patients supporting the potential of the candidate as a novel payload BCMA-targeted ADC therapy.

Details of the poster presentation (HDP-102):

Presentation title: HDP-102, a first-in-class CD37-targeted amanitin-based antibody-drug conjugate, demonstrates translational activity, favorable early safety and efficacy in relapsed/refractory (R/R) B-cell malignancies

HDP-102 is an ADC targeting CD37, which is overexpressed on B-cell lymphoma cells. Preclinical studies have shown excellent anti-tumor efficacy in in vivo studies as well as good tolerability. HDP-102 is intended to be developed for specific indications of non-Hodgkin lymphoma.

In 2025, Heidelberg Pharma announced the dosing of the first patient with HDP-102. Three patients were treated with 40 µg/kg in the first cohort. The treatment was well tolerated, and initial signs of biological activity have been observed already at the very low dose. Two patients showed stabilization of the disease with regression and reduction of lymph nodes. The safety committee recommended increasing the dose of HDP-102 to 65 µg/kg in cohort 2.

In line with Heidelberg Pharma’s strategic decision from September 2025 to discontinue the study, the Company is exploring partnership opportunities to support the continuation of the program.

About Heidelberg Pharma

Heidelberg Pharma is the first company to develop cancer therapies using Amanitin, a compound derived from the green death cap mushroom. The biological mechanism of action of the toxin represents a new therapeutic modality and is used as a compound in the Amanitin-based ADC technology, the so-called ATAC technology.

Lead candidate HDP-101 (INN: pamlectabart tismanitin) is a BCMA ATAC in clinical development for multiple myeloma. The candidate has been granted Orphan Drug Designation and Fast Track Designation from the FDA. A second ATAC candidate, HDP-102 is in clinical development stage in Non-Hodgkin Lymphoma. HDP-103 against metastatic castration-resistant prostate cancer and HDP-104 targeting gastrointestinal tumors such as colorectal cancer have completed preclinical development. These programs are available for partnering.

The company is based in Ladenburg, Germany, and is listed on the Frankfurt Stock Exchange: ISIN DE000A11QVV0 / WKN A11QVV / Symbol HPHA. More information is available at http://www.heidelberg-pharma.com/.

ATAC^® is a registered trademark of Heidelberg Pharma Research GmbH.

This communication contains certain forward-looking statements relating to the Company’s business, which can be identified by the use of forward-looking terminology such as “estimates”, “believes”, “expects”, “may”, “will” “should” “future”, “potential” or similar expressions or by a general discussion of the Company’s strategy, plans or intentions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results of operations, financial condition, performance, or achievements, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Given these uncertainties, prospective investors and partners are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such forward-looking statements to reflect future events or developments.